



Recommendations on Reporting on HER2 Status in Breast Cancer Patients

The NCCP Molecular Diagnostics Advisory Group have made the following recommendations in relation to reporting on HER2 status in breast cancer patients.

- All HER2 testing results for breast cancer patients should indicate the IHC result (HER2-0, HER2-1+, HER2-2+/ISH not amplified, HER2-2+ /ISH amplified or HER2-3+).
- Reassessment of HER2-0 results may be required in specific patient cohorts at the request of Consultant Medical Oncologist as distinction between 0/1+ was previously not clinically relevant.
- HER2 testing results close to the 0 versus 1+ interpretative threshold should be examined at high power magnification and consideration given to second pathologist review as needed.

Recommendation Date : 11/03/2024